Actinium Pharmaceuticals, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsActinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology, with no commercial revenue and a pipeline focused on solid tumors and hematologic malignancies.
What they do
Actinium is developing targeted radiopharmaceuticals using antibodies conjugated to isotopes like Actinium-225. Its pipeline includes ATNM-400, a first-in-class Ac-225 antibody radioconjugate targeting a novel antigen for solid tumors; Actimab-A, a CD33-targeted therapy for AML/MDS and solid tumors; and Iomab-B and Iomab-ACT, CD45-targeting conditioning agents for bone marrow transplant and cell/gene therapies.
Revenue drivers
- No commercial products — The company generates no revenue from product sales; revenue has been minimal (e.g., $90,000 in 2025, $35.0M in Q2 2026 from licensing or grants, per financials).
- Grant and collaboration revenue — Revenue streams come from partnerships like the NCI collaboration for Actimab-A and other research funding, though amounts are immaterial relative to operating costs.
- Potential future product sales — Future revenue would depend on approval and commercialization of pipeline candidates such as ATNM-400, Actimab-A, Iomab-B, and Iomab-ACT, all still in development.
Recent performance
In Q2 2026, the company reported revenue of $35.0M, a significant jump from the $90,000 in the year-ago quarter, likely due to a one-time license or collaboration event. Net losses have narrowed from $-48.8M in 2023 to $-33.9M in 2025, with 2025 diluted EPS at $-1.09. Operating cash flow improved from $-47.3M in 2023 to $-24.6M in 2025. As of June 30, 2026, the company had cash and equivalents of $36.5M, total assets of $40.2M, and shareholder equity of $30.3M.
Strategy
Actinium is focused on developing first-in-class radiopharmaceuticals targeting differentiated biological targets beyond PSMA and SSTR2, aiming for pan-tumor potential. The company is leveraging its radiochemistry expertise and translational medicine to build a pipeline across solid tumors (via ATNM-400 and Actimab-A) and hematologic conditions (Iomab-B, Iomab-ACT). It is also partnering with the NCI for Actimab-A in AML/MDS and plans to report data from ongoing studies in late 2026 and 2027.
Risks
- No commercial revenue — The company has not generated product sales and may never do so; it expects continued net losses and needs additional financing to complete development.
- Clinical and regulatory uncertainty — Pipeline candidates like ATNM-400 and Iomab-ACT are in early or late-stage development, and there is no guarantee of regulatory approval or commercial success.
- Dependence on key personnel — The company's success relies heavily on retaining highly qualified personnel in a competitive biotech talent market, which may be difficult.
- Financing risk — If the company fails to raise additional capital, it may be unable to continue or complete product development, potentially leading to a loss of investment.
Outlook
Management expects to report data from ongoing company- and investigator-sponsored studies for ATNM-400, Actimab-A (for MDSCs), and Iomab-ACT in 4Q 2026 and through 2027. The company anticipates continuing net losses and will likely need additional financing to fund operations and clinical development. The radiopharmaceutical market's growth, as evidenced by blockbuster products like Pluvicto, provides a supportive backdrop for the company's differentiated asset strategy.